Nanoform Finland and Herantis Pharma say that they have successfully demonstrated the feasibility of using Nanoform’s nanoparticle technology for a potential intranasal formulation of Herantis’s cerebral dopamine neurotrophic factor (CDNF) for the treatment of Parkinson’s disease, with the protein remaining stable and active following processing.
The two companies announced their plans for the proof of concept study in February 2021. According to the latest announcement, Nanoform and Herantis will now conduct a proof of process study to optimize the CDNF particles for nasal delivery.
Nanoform Chief Commercial Officer Christian Jones said, “We are excited with these initial results that show nanoforming is effective with Herantis’ rhCDNF program. This POC study with Herantis Pharma’s rhCDNF further validates the wide applicability of Nanoform’s technologies to a diverse range of molecules. We look forward to now moving into a POP study and further nanoforming activities as rhCDNF continues its development.”
Herantis Pharma CEO Craig Cook commented, “This was a key milestone to achieve as part of our broader intranasal administration project for rhCDNF, one of only a few clinical stage assets focused on disease modification of Parkinson’s disease. The ability to nanoform the rhCDNF molecule improves the chances of success for intranasal administration and creates additional possibilities to impact the lives of patients. We very much look forward to progressing the work with Nanoform.”
Read the Nanoform press release.
